KUALA LUMPUR, Nov 20 -- PRA Health Sciences Inc has announced the appointment of Isaac Rodriguez-Chavez, PhD, MHS, MS, as Senior Vice-President, Scientific and Clinical Affairs to lead the company’s Global Center of Excellence for Decentralized Clinical Trial (DCT) Strategy.
His responsibilities involves the continued growth and development of PRA’s industry-leading decentralised clinical trial strategy, regulatory framework creation, and clinical trial modernisation.
Having more than 32 years’ experience in virology, microbiology, immunology, vaccinology and viral oncology, among others, he was most recently, a Senior Officer for Clinical Research Methodologies, Regulatory Compliance, and Medical Policy Development with the US Food and Drug Administration’s Center for Drug Evaluation and Research.
In a statement, PRA President and Chief Executive Officer (CEO), Colin Shannon said: "The clinical drug development paradigm continues to evolve into a more decentralised model to better align with how healthcare is delivered to individuals.”
“By pairing Dr Rodriguez-Chavez, one of the leading experts in decentralised clinical trials, with PRA’s state-of-the-art DCT platform, we will modernise the clinical trial process.”
Dr Rodriguez-Chavez said PRA Health Sciences had the vanguard infrastructure, human capital, and experience to provide excellence in a global suite of clinical research and healthcare services
Prior to his work with the FDA, Dr Rodriguez-Chavez was founder and CEO of 4Biosolutions Consulting and was the Vice-President for Research at the Texas Biomedical Research Institute.
More details at www.prahs.com.
-- BERNAMA
No comments:
Post a Comment